Prof Stephen Nicholls

Director, Victorian Heart Hospital and Victorian Heart Institute, Clayton, Australia

Assoc Prof David Sullivan

Physician and Chemical Pathologist, Department of Clinical Biochemistry, Royal Prince Alfred Hospital, New South Wales, Australia

Assoc Prof Karam Kostner

Director of Cardiology, Mater Public and Private Hospital, Brisbane, Australia

Home > Education & CME > Webinar > Lipoprotein(a): The science behind the Risk Factor

Lipoprotein(a): The science behind the Risk Factor

6 May 2024

KEY TAKEAWAYS

Higher Lipoprotein(a) levels are associated with increased rate of CVD. The recent 2019 ESC guidelines recommend Lp(a) biomarker testing at least once in each adult person’s life.
Challenges to implementation of Lp(a) biomarker testing include access, feasibility, affordability and impact on outcomes.
Patients with elevated Lipoprotein(a) levels with elevated risk of CVD should be treated to reduce LDL levels.

Updates from Leading Experts

STRONG-HF: Post-discharge Heart Failure Management and Implementation of GDMT Heart Failure Therapy

Prof Alexandre Mebazaa shares the key results and highlights from the STRONG-HF study that assessed the safety, tolerability of optimization of guideline directed medical therapy.

28 March 2023

Prof Alexandre Mebazaa

CANVAS study: NT-proBNP and CVD risk reduction

Can you give us a short description of the CANVAS program? The CANVAS program was a set of two trials, whose goal was to evaluate the role of an SGLT2...

1 July 2021

Dr James L Januzzi